Ovitrelle 250 micrograms solution for injection in pre-filled pen

DRUG4 trials

Sponsors

Ferring Pharmaceuticals A/S, Santiago Dexeus Font Fundacio Privada, Institut De Cancerologie De L Ouest, Centre Hospitalier Intercommunal Creteil

Conditions

Breast cancerInfertilityInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycleinfertility

Phase 2

Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer (PRESAGE)

RecruitingCTIS2024-516282-37-00

Institut De Cancerologie De L OuestBreast cancer

Start: 2025-02-18Target: 100Updated: 2024-08-09

Using a fixed dosage of follitropin delta for ovarian stimulation for intrauterine insemination. Rekovelle for Intrauterine Successful Experience (RISE )

RecruitingCTIS2025-520681-22-00

Centre Hospitalier Intercommunal CreteilInfertility

Start: 2025-12-17Target: 80Updated: 2025-07-31

Phase 3

A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the ovarian response after controlled ovarian stimulation with mixed protocols of follitropin delta (REKOVELLE) and highly purified human menopausal gonadotropin (MENOPUR) in women undergoing an assisted reproductive technology programme

Not yet recruitingCTIS2022-500308-23-00

Ferring Pharmaceuticals A/SInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle

Target: 115Updated: 2022-11-09

Phase 4

PErsonalized Addition of Recombinant LH in suboptimal responders >35 years old (POSEIDON group 2). A randomized controlled trial

Not yet recruitingCTIS2024-514035-19-00

Santiago Dexeus Font Fundacio Privadainfertility

Target: 120Updated: 2024-09-23